}

Myriad Genetics to Acquire Counsyl for $375M

Posted on by Drea

May 29, 2018

GenomeWeb – Staff Reporter

NEW YORK (GenomeWeb) — Myriad Genetics is acquiring genetic screening firm Counsyl for $375 million in cash and common stock, the molecular diagnostics firm said last night. The move is a bid to bolster its position in the women’s health space.

The acquisition will allow Myriad, a leader in the hereditary cancer genetic screening market, to expand into carrier screening with Counsyl’s Foresight test, which covers more than 175 clinically actionable conditions across ethnicities, and into the rapidly growing noninvasive prenatal screening market with Counsyl’s Prelude test.

Read Full Article

This entry was posted in News. Bookmark the permalink.

Comments are closed.

Share This
twitter.com
LinkedIn.com
website by filias + APART